TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease
- PMID: 33475057
- DOI: 10.2174/1389450122999210120205607
TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease
Abstract
Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), are chronic inflammatory diseases of the gastrointestinal tract. In the last few years, the development of biological agents targeting cytokines and receptors involved in IBD pathogenesis has led to better outcomes and has improved the course of the disease. Despite their effectiveness, drugs such as tumor necrosis factor (TNF) inhibitors, anti-Interleukin-12/23 and anti-integrins, do not induce a response in about one-third of patients, and 40% of patients lose response over time. Therefore, more efficient therapies are required. Recent studies showed that TL1A (Tumor necrosis factor-like cytokine 1A) acts as a regulator of mucosal immunity and participates in immunological pathways involved in the IBD pathogenesis. In this review article, we analyze the role of TL1A as a new potential target therapy in IBD patients.
Keywords: Crohn's disease; DR3; Inflammatory Bowel Diseases; TL1A; Ulcerative colitis; anti-TL1A; fibrosis; inflammation; mucosal immune system.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis.Med. 2024 May 10;5(5):386-400. doi: 10.1016/j.medj.2024.03.010. Epub 2024 Apr 3. Med. 2024. PMID: 38574740 Review.
-
TL1A (TNFSF15) and DR3 (TNFRSF25): A Co-stimulatory System of Cytokines With Diverse Functions in Gut Mucosal Immunity.Front Immunol. 2019 Mar 27;10:583. doi: 10.3389/fimmu.2019.00583. eCollection 2019. Front Immunol. 2019. PMID: 30972074 Free PMC article. Review.
-
TL1A as a Potential Local Inducer of IL17A Expression in Colon Mucosa of Inflammatory Bowel Disease Patients.Scand J Immunol. 2015 Oct;82(4):352-60. doi: 10.1111/sji.12324. Scand J Immunol. 2015. PMID: 26072972
-
Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis.Inflamm Bowel Dis. 2022 Mar 2;28(3):434-446. doi: 10.1093/ibd/izab193. Inflamm Bowel Dis. 2022. PMID: 34427649 Free PMC article.
-
The tumor necrosis factor-like cytokine 1A/death receptor 3 cytokine system in intestinal inflammation.Curr Opin Gastroenterol. 2013 Nov;29(6):597-602. doi: 10.1097/MOG.0b013e328365d3a2. Curr Opin Gastroenterol. 2013. PMID: 24100723 Review.
Cited by
-
Dysregulation of CD4+ and CD8+ resident memory T, myeloid, and stromal cells in steroid-experienced, checkpoint inhibitor colitis.J Immunother Cancer. 2024 Apr 19;12(4):e008628. doi: 10.1136/jitc-2023-008628. J Immunother Cancer. 2024. PMID: 38642938 Free PMC article.
-
TL1A promotes metastasis and EMT process of colorectal cancer.Heliyon. 2024 Jan 15;10(2):e24392. doi: 10.1016/j.heliyon.2024.e24392. eCollection 2024 Jan 30. Heliyon. 2024. PMID: 38312710 Free PMC article.
-
Speos: an ensemble graph representation learning framework to predict core gene candidates for complex diseases.Nat Commun. 2023 Nov 8;14(1):7206. doi: 10.1038/s41467-023-42975-z. Nat Commun. 2023. PMID: 37938585 Free PMC article.
-
Inflammatory Bowel Disease: Emerging Therapies and Future Treatment Strategies.Biomedicines. 2023 Aug 11;11(8):2249. doi: 10.3390/biomedicines11082249. Biomedicines. 2023. PMID: 37626745 Free PMC article. Review.
-
Trans-ancestry, Bayesian meta-analysis discovers 20 novel risk loci for inflammatory bowel disease in an African American, East Asian and European cohort.Hum Mol Genet. 2023 Feb 19;32(5):873-882. doi: 10.1093/hmg/ddac269. Hum Mol Genet. 2023. PMID: 36308435 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
